YI.NASDAQ111, INC
20-F: 111, Inc. Files 20-F Report: Details Financial Performance and Regulatory Landscape
Sentiment:
Annual Results
111, Inc. releases its annual report on Form 20-F, providing a comprehensive overview of its financial results, operational activities, and the regulatory environment impacting its business in China.
Summary
- 111, Inc., a Cayman Islands-based company, conducts its primary operations in China through its PRC subsidiaries.
- The company's 20-F filing includes audited consolidated financial statements prepared in accordance with U.S. GAAP.
- In 2023, 111, Inc.'s revenue reached RMB 14.9 billion (approximately US$2.1 billion), with B2B product revenues accounting for RMB 14.5 billion (approximately US$2.0 billion).
- The company reported a net loss of RMB 353.4 million (approximately US$49.8 million) for 2023.
- The report details the company's organizational structure, including its subsidiaries and their respective ownership.
- The document outlines various risks associated with operating in China, including regulatory uncertainties, economic conditions, and potential delisting under the Holding Foreign Companies Accountable Act (HFCAA).
- The filing also discusses the company's internal controls, corporate governance practices, and compliance with relevant laws and regulations.
- The company is actively working to address potential issues related to a proposed STAR Market listing for one of its subsidiaries and related redemption obligations.
Sentiment
Score: 6
Explanation: The document presents a mixed sentiment. While revenue growth is positive, the continued net losses and regulatory risks temper the overall outlook. The company's efforts to address financial and operational challenges are noted, but uncertainties remain.
Positives
- Revenue increased by 10.6% from 2022 to 2023, driven by growth in the B2B segment.
- Net loss decreased from RMB 376.1 million in 2022 to RMB 353.4 million in 2023.
- The company has implemented a share repurchase program.
- The company has taken steps to address potential issues related to a proposed STAR Market listing for one of its subsidiaries.
Negatives
- The company reported a net loss of RMB 353.4 million (approximately US$49.8 million) for 2023.
- The company faces risks associated with operating in China, including regulatory uncertainties and potential delisting under the HFCAA.
- The company is working to extend the deadline for redeeming contingently redeemable non-controlling interests in 1 Pharmacy Technology, indicating potential financial strain.
Risks
- Uncertainties in the interpretation and enforcement of PRC laws and regulations.
- Potential for the company's ADSs to be delisted under the Holding Foreign Companies Accountable Act (HFCAA).
- Restrictions on foreign exchange and the ability to transfer cash between entities across borders.
- Evolving regulatory requirements related to cybersecurity, information security, and data privacy.
- Intense competition in the PRC general health and wellness market.
- Inability to achieve or maintain profitability.
- Potential product liability and medical liability claims.
- Failure to complete the STAR Market listing for 1 Pharmacy Technology.
- Reliance on third-party logistics and delivery companies.
- Potential for security breaches and cyberattacks.
- Potential for the company to be classified as a PRC resident enterprise for tax purposes.
- Volatility in the trading price of the ADSs.
Future Outlook
The company expects to continue its growth trajectory by attracting more pharmacies as customers and expanding its offline pharmacy market. It also aims to create more value for participants in the healthcare ecosystem and increase monetization through innovative cloud-based solutions and smart supply chain services.
Industry Context
The company operates in the rapidly evolving PRC general health and wellness market, which is characterized by intense competition, changing government regulations, and evolving customer preferences. The company aims to be a leading digital healthcare platform in China by connecting patients with medicine and healthcare services digitally.
Comparison to Industry Standards
- The document does not provide enough information to make a detailed comparison to industry standards.
- Without specific details on metrics like customer acquisition cost, average order value, or inventory turnover, a benchmark comparison is not possible.
- Comparable companies in the online pharmacy and healthcare space include Ali Health and JD Health, but a meaningful comparison would require more granular data.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Clawback Policy | The Board of Directors adopted a Compensation Recoupment Policy to recover certain executive compensation in the event of an accounting restatement resulting from material noncompliance with financial reporting requirements. | September 7, 2023 | This policy aims to comply with Section 10D of the Exchange Act and Section 5608 of the Nasdaq Listing Rules, enhancing corporate governance and accountability. |
Legal Proceedings
- The company is involved in legal arbitration with one of the investors in 1 Pharmacy Technology regarding the redemption of its noncontrolling interest, with approximately RMB36.1 million in dispute.
Related Party Transactions
- The document mentions the termination of contractual arrangements with former variable interest entities (VIEs) and the acquisition of direct equity ownership in these entities.
- It also discusses a strategic cooperation agreement with Xian Beilin Pharmaceutical Co., Ltd. and Shenzhen BGI Genomics Co., Ltd.
Stakeholder Impact
- Shareholders: The company's financial performance and regulatory compliance directly impact shareholder value.
- Employees: The company's share incentive plans and employee benefit plans affect employee compensation and benefits.
- Customers: The company's ability to provide quality products and services at competitive prices impacts customer satisfaction.
- Suppliers: The company's relationships with suppliers and its ability to obtain favorable terms affect its cost of goods sold.
- Creditors: The company's ability to meet its debt obligations impacts its relationships with creditors.
Next Steps
- Continue to navigate the regulatory landscape in China.
- Work to extend the deadline for redeeming contingently redeemable non-controlling interests in 1 Pharmacy Technology.
- Focus on achieving and sustaining profitability.
- Implement strategies to attract and retain customers and pharmacies.
- Enhance technologies and IT infrastructure to create more value for participants in the healthcare ecosystem.
Key Dates
| Date | Description |
|---|---|
| 1982 | Gang Yu received his bachelors degree in science from Wuhan University. |
| 1984 | Lian Yong Chen obtained his Bachelor of Science degree in Chemistry from Peking University. |
| 1986 | Gang Yu received masters degree in physics from Cornell University. |
| 1990 | Gang Yu received Ph.D. degree in decision sciences from The Wharton School of the University of Pennsylvania. |
| 1991 | Junling Liu received his bachelors degree in education from Flinders University in Australia. |
| 1991 | Lian Yong Chen conducted postdoctoral research at the Massachusetts Institute of Technology after obtaining his Ph.D. degree in Chemistry from the University of Louvain, Louvain-La-Neuve in Belgium. |
| 1994 | Jun Luo received his bachelors degree in accounting from Shanghai University of Finance and Economics. |
| 1998 | Junling Liu received masters degree in international business administration from Flinders University in Australia. |
| 2000 | Founders launched 1 Drugstore, one of the first online retail pharmacies in China. |
| 2008 | Junling Liu served as chief executive officer of YHD.com. |
| 2010 | Founders launched 1 Medicine Marketplace. |
| January 2013 | Yihao Pharmaceutical Chain established its subsidiary Shanghai Yaowang E-Commerce Co., Ltd. |
| May 2013 | Yao Wang Holdings Ltd. was incorporated under the laws of the Cayman Islands as our offshore holding company. |
| June 2013 | Yao Wang Corporation Limited was incorporated in Hong Kong as a wholly owned subsidiary of 111, Inc. |
| August 2013 | 1 Pharmacy Technology (Shanghai) Co., Ltd. was established as a wholly owned subsidiary of Yao Wang in the PRC. |
| September 2013 | 1 Pharmacy Technology entered into a series of contractual agreements with Guangdong Yihao Pharmacy Co., Ltd., Yihao Pharmaceutical Chain and Shanghai Yaowang. |
| January 2015 | Junling Liu has been an independent director of Autohome Inc. |
| 2016 | Commenced online medical services through internet hospital, 1 Clinic. |
| September 15, 2018 | ADSs commenced trading on Nasdaq under the symbol YI. |
| May 2019 | Lian Yong Chen has served as our director. |
| August 17, 2020 | 1 Pharmacy Technology completed the capital injection from new investors with an aggregate of RMB419.82 million. |
| December 22, 2020 | 1 Pharmacy Technology completed another round of financing with an aggregate of RMB515 million. |
| May 2021 | Yijianyikang Medical Technology (Shanghai) Co., Ltd. initiated the 1 Health Membership program. |
| February 2022 | Terminated the contractual arrangements between 1 Pharmacy Technology and the VIEs. |
| September 9, 2022 | Board of directors received an unsolicited preliminary non-binding proposal letter from the Co-Founders and Shanghai Guosheng Capital Management Co., Ltd. |
| December 1, 2022 | The Online Drug Sales Measures were promulgated by the SAMR and took effect. |
| February 17, 2023 | The CSRC promulgated the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies, which came into effect on March 31, 2023. |
| February 27, 2024 | Received a notice from the Buyer Group, stating that it would withdraw its Proposals and formally terminate further negotiation with the special committee of our board of directors regarding the transactions contemplated by the Proposal. |
| April 2024 | Shang Yaowang was dissolved. |
| July 1, 2024 | China enacted its amended Company Law, which will come into effect. |
Keywords
pharmacy, healthcare, China, regulatory, financial results, B2B, B2C, ADS, HFCAA, VIE, listing, cybersecurity, data privacy
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.